Market capitalization | $13.56m |
Enterprise Value | $3.75m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.07 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-16.23m |
Free Cash Flow (TTM) Free Cash Flow | $-17.13m |
Cash position | $10.04m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a Cingulate forecast:
2 Analysts have issued a Cingulate forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.67 -0.67 |
20%
20%
|
|
EBITDA | -16 -16 |
22%
22%
|
EBIT (Operating Income) EBIT | -16 -16 |
21%
21%
|
Net Profit | -16 -16 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Head office | United States |
CEO | Shane Schaffer |
Employees | 13 |
Founded | 2013 |
Website | www.cingulate.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.